Suppr超能文献

新一代酪氨酸激酶抑制剂相关无症状性脑血管狭窄:两例说明性病例。

New-generation tyrosine kinase inhibitor-associated asymptomatic cerebrovascular stenosis: two illustrative cases.

机构信息

Department of Neurosurgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

出版信息

Acta Neurochir (Wien). 2022 Jun;164(6):1623-1626. doi: 10.1007/s00701-021-05043-3. Epub 2021 Nov 26.

Abstract

New-generation tyrosine kinase inhibitors (TKIs), nilotinib and ponatinib, for chronic myelogenous leukemia (CML) have been reported to cause symptomatic cerebral ischemia. Herein, we report two patients with asymptomatic cerebral artery stenosis associated with these TKIs, as a previously unreported finding. Both patients were in their 40 s and administered new-generation TKIs without vascular risk factors. New-generation TKIs for CML can cause major cerebrovascular stenosis without any symptoms. Examining the neck and intracranial arteries using magnetic resonance angiography and carotid ultrasonography may prevent future cerebral infarctions associated with these TKIs.

摘要

新型酪氨酸激酶抑制剂(TKI)尼洛替尼和达沙替尼治疗慢性髓性白血病(CML)可引起症状性脑缺血。在此,我们报告两例新型 TKI 治疗相关无症状性颅内动脉狭窄患者,这是一种以前未报道的发现。两例患者均为 40 多岁,无血管危险因素,应用新型 TKI 治疗 CML。新型 TKI 治疗 CML 可导致无任何症状的大血管狭窄。使用磁共振血管造影和颈动脉超声检查颈部和颅内血管可能预防与这些 TKI 相关的未来脑梗死。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验